All Updates

All Updates

icon
Filter
Funding
Management news
HDAX Therapeutics raises USD 3.2 million in seed funding to progress pipeline and advance preclinical candidates into trials
Precision Medicine
Sep 5, 2024
This week:
Partnerships
Microsoft and BlackRock partner to launch USD 30 billion AI data center investment fund
Machine Learning Infrastructure
Today
Funding
Limitless Labs raises USD 3 million in pre-seed funding to develop prediction market
Web3 Ecosystem
Today
Product updates
Google Cloud launches Blockchain RPC service for Web3 developers
Web3 Ecosystem
Today
Product updates
Kore.ai launches GALE platform for enterprise GenAI adoption
Machine Learning Infrastructure
Today
Product updates
Kore.ai launches GALE platform for enterprise GenAI adoption
Generative AI Infrastructure
Today
Product updates
ProAmpac launches enhanced online pouch configurator MAKR by DASL for custom flexible packaging prototypes
Smart Packaging Tech
Yesterday
Funding
M&A
Majority stake in Bollegraaf Group acquired by Summa Equity for EUR 800 million
Waste Recovery & Management Tech
Yesterday
Partnerships
NASA awards Intuitive Machines contract for near-space network services
Space Travel and Exploration Tech
Yesterday
Partnerships
FinFit partners with Sunny Day Fund to offer emergency savings accounts
Financial Wellness Tools
Yesterday
Partnerships
KSP partners with Peak Technologies and Locus Robotics for warehouse automation
Logistics Tech
Yesterday
Precision Medicine

Precision Medicine

Sep 5, 2024

HDAX Therapeutics raises USD 3.2 million in seed funding to progress pipeline and advance preclinical candidates into trials

Funding
Management news

  • HDAX Therapeutics has raised USD 3.2 million in an oversubscribed seed funding round led by SeedFolio, FACIT, and Toronto Innovation Acceleration Partners (TIAP), with participation from Eos Bioinnovation and Ontario Centre of Innovation, among other investors.

  • The funds are planned to be directed toward advancing the company's preclinical candidate nomination and the progression of its pipeline programs. In parallel with the funding, CEO of Eos and vice president at TIAP have joined the HDAX board of directors.

  • HDAX Therapeutics is a biotechnology company developing novel small molecule therapeutics targeting HDAC6 (Histone Deacetylase 6) for neurological, cardiac, and metabolic disorders. The company's proprietary technology uses a unique two-site binding mechanism to create potent and selective HDAC6 inhibitors, addressing key challenges in drug design such as weak binding, poor pharmacokinetics, and off-target toxicities.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.